Combination immunotherapy and chemotherapy for extensive-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study is testing a new combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus standard chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this combination can be more effective than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with extensive-stage small cell lung cancer.
- You have not had previous treatment for extensive-stage SCLC, or you have only had one prior type of immunotherapy (PD-1/PD-L1) combined with chemotherapy.
- You can perform daily activities (ECOG performance status 0-2).
- Your liver, kidney, and blood functions are within acceptable limits.
- You agree to provide a small sample of your tumor tissue for testing.
- You are willing to use reliable birth control during the trial if you are of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a combination of the immunotherapy drug Adebrelimab plus chemotherapy together with radiation (given at the same time) is better than giving radiation after chemo for people with extensive-stage small cell lung cancer who haven't been treated before.
This trial tests a combination of benmelstobart (an immunotherapy drug), anlotinib (a targeted therapy that blocks blood vessel growth), chemotherapy, and chest radiation for people with extensive-stage small cell lung cancer (cancer that has spread beyond one lung). The goal is to see if this combination helps shrink tumors and control the disease better than standard care.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of chemotherapy (platinum/etoposide) plus an immunotherapy drug (ivonescimab) for people with extensive-stage small cell lung cancer who have not received treatment before. The goal is to see if adding the immunotherapy improves outcomes.
This trial tests a new combination of two immunotherapy drugs plus chemotherapy, followed by radiation to the chest, for people with extensive-stage small cell lung cancer who have not been treated yet. The goal is to see if this approach can shrink the cancer and help people live longer.
This trial tests a new combination of two drugs for people with extensive-stage small cell lung cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
Hear when a new SCLC, Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.